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Cardiovascular diseaseSilent information regulator-2 (Sir-2) proteins, or sirtuins, are a highly conserved protein family of histone
deacetylases that promote longevity by mediating many of the beneﬁcial effects of calorie restriction which ex-
tends life span and reduces the incidence of cancer, cardiovascular disease (CVD), and diabetes. Here, we review
the role of sirtuins (SIRT1-7) in vascular homeostasis and diseases by providing an update on the latest knowl-
edge about their roles in endothelial damage and vascular repair mechanisms. Among all sirtuins, in the light
of the numerous functions reported on SIRT1 in the vascular system, herein we discuss its roles not only in the
control of endothelial cells (EC) functionality but also in other cell types beyond EC, including endothelial progen-
itor cells (EPC), smooth muscle cells (SMC), and immune cells. Furthermore, we also provide an update on the
growing ﬁeld of compounds under clinical evaluation for the modulation of SIRT1 which, at the state of the art,
represents the most promising target for the development of novel drugs against CVD, especially when concom-
itant with type 2 diabetes.
© 2015 Published by Elsevier B.V.1. Introduction
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Balestrieri).cardiovascular diseases (CVD), such as hypercholesterolemia, hyperten-
sion, smoking, and diabetes. Speciﬁcally, the complex phenomenon of
vascular dysfunction involves aging-related deterioration of the vascu-
lature and secondary stresses, such asmetabolic disorders, altered nitric
oxide (NO) pathway, and increased inﬂammation and oxidative stress
[1–5]. Particularly, the reduction of NO bioavailability caused by its di-
minished synthesis and/or by its augmented scavenging due to oxida-
tive stress, along with the increased platelet aggregation, cytokines
production, and adhesion molecule and chemokine expression, are the
main intracellular events leading to endothelial dysfunction and vascu-
lar damage [1–5].
The epigenetic changes of histone and non-histone protein
deacetylation catalyzed by sirtuins, or silent information regulator
2 (Sir2) proteins, take part to the mechanisms regulating vascular
dysfunction related to aging, CVD and, most of all, vascular complica-
tions during diabetes [1,6–9]. Beyond controversy about the inﬂuence
of Sir2 on lifespan extension in Caenorhabditis elegans and Drosophila
melanogaster [10–12], the ﬁrst evidence showing the connection be-
tween sirtuins and aging is the observations that overexpression of the
sirtuin member Sir2 was able to extend lifespan in yeast, C. elegans,
and in D. melanogaster [13]. Sirtuins, ﬁrstly described as modulators of
energy metabolism, DNA repair, and oxidative stress responses [13]
are known to exert protective effects against age-related diseases such
as CVD, cancer, diabetes, and neurodegenerative diseases [13–15].
Mammals hold sevenmembers of the sirtuin family, from SIRT1, the
most extensively characterized for its role in aging, to SIRT7, all
possessing a common highly conserved catalytic domain and nicotin-
amide adenine dinucleotide (NAD+)-binding site. They have different
subcellular localization, tissue speciﬁcity, activity, and targets [16].
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nucleus to cytosol occurs following speciﬁc conditions [17]. SIRT2 is
cytosolic but also nuclear in certain phase of the cell cycle [18]. SIRT3,
SIRT4 and SIRT5 are mitochondrial [19], while SIRT6 and SIRT7 are nu-
clear and nucleolar, respectively [20,21]. As for the catalytic activities,
SIRT1, SIRT2, SIRT3, SIRT5 SIRT6 and SIRT7 act as deacetylase enzymes
using NAD+ to cleave acetyl groups from ε-acetyl lysine residues of
target proteins in a reaction that generates nicotinamide (NAM), 2′-O-
acetyl-ADP-ribose, and deacetylated substrates [22] (Fig. 1).
SIRT4, as well as SIRT6, acts as a mono-ADP-ribosyltransferase, in a
reaction where the ADP-ribosyl moiety of NAD+ is transferred to a
substrate protein [19,23]. It has been demonstrated that SIRT4 acts as
lipoamidase that regulates the pyruvate dehydrogenase complex
(PDH) and, importantly, its catalytic efﬁciency for lipoyl- and biotinyl–
lysine modiﬁcations is superior to its deacetylation activity [24]. As for
SIRT6, this deacetylase can locate at the endoplasmic reticulumand con-
trols protein lysine fatty acylation [25]. Indeed, as revealed by crystal
structure, SIRT6possesses a large hydrophobic pocket able to accommo-
date long chain fatty acyl groups and efﬁciently remove them from
lysine residues [25]. Beside the deacetylase activity, SIRT5 also shows
demalonylase and desuccinylase activity [26] (Fig. 1).
Sirtuin chromatin-associated functions are also exerted through the
modulation of epigenetic information by direct deacetylation of speciﬁc
histone acetylation marks [27]. Among mammalian sirtuins, SIRT1
and SIRT6 are the most functionally important deacetylase of histoneFig. 1. Enzymatic activities of sirtuins. The seven sirtuins are categorized into four classes, class
Mammalian sirtuins have primarily two different NAD+-consuming activities. SIRT1, SIRT2, SIR
from ε-acetyl lysine residues of target proteins in a reaction that generatesNAMand 2′-O-acetyl-
ADP-ribosylmoiety of NAD+ is transferred to a substrate protein. SIRT6 has both enzymatic acti
over, SIRT4 acts as a cellular lipoamidase and SIRT5 acts as demalonylase and desuccinylase, by r
adenine dinucleotide; NAM, nicotinamide; ADP: adenosine diphosphate.(H) 3 acetylated (Ac) on lysine (K) 9 (H3K9Ac). SIRT1 deacetylation of
H3K9Ac and H4K16Ac is directly associated with its capacity to coordi-
nate the formation of constitutive and facultative heterochromatin [27].
Other histone substrates of SIRT1 are H1K27Ac, H3K9Ac, H3K14Ac,
H3K18Ac, H3K56Ac, H4K12Ac, and H4K6Ac. SIRT6 H3K9Ac deacetylase
activity is important for modulating telomere structure and DNA repair
of double-strand breaks [27].
Given the array of potentially beneﬁcial effects of sirtuinmodulation
on cardiovascular health, the interest in developing speciﬁc modulators
is keeping increasing [28–30]. Indeed, although the role of SIRT1 on
longevity per se is not fully convincing because transgenic mice over-
expressing SIRT1 did not show to live longer than controls, to date,
the efﬁcacy of SIRT1 in protecting mice against age-associated diseases
unveils an important role in improving health span and preventing
CVD [14,31]. At vascular level, given that all seven sirtuins are expressed
in vascular endothelial cells (EC), SIRT1 is the only member of the
sirtuin family shown to uniquely regulate EC physiology by promoting
vasodilatory and regenerative functions of the vascular wall through
the modulation of endothelial nitric oxide synthase (eNOS) activity,
forkhead box O1 (FOXO1), p53, and angiotensin II (Ang II) type 1 recep-
tor (AT1R) [28,32,33].
Over the recent years, in addition to SIRT1, the function of other
sirtuins in vascular physiology has been investigated and some of
them are likely to have roles in the normal and diseased blood vessels.
Among these, recent advances have been made on the role of SIRT3, aI (SIRT1, SIRT2, and SIRT3), class II (SIRT4), class III (SIRT5), and class IV (SIRT6 and SIRT7).
T3, SIRT5 SIRT6 and SIRT7 act as deacetylase enzymes using NAD+ to cleave acetyl groups
ADP-ribose. SIRT4 and SIRT6 act as amono-ADP-ribosyltransferase, in a reactionwhere the
vities and, also, efﬁciently removes long chain fatty acyl groups from lysine residues. More-
emovingmalonyl (Mal) or succinylmoiety (Suc) from target proteins. NAD+, nicotinamide
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syndrome and, most of all, on SIRT6, a chromatin-associated sirtuin
which transmits its signals through histone deacetylation [9,23,34].
Herein, we review the current knowledge on the roles of sirtuins in
vascular homeostasis and diseases, with emphasis on the molecular
mechanism underlying their protective role at vascular level. Moreover,
we also examine the potential clinical application of sirtuin modulators
in the development of novel therapeutic strategies to treat endothelial
dysfunction in CVD and vascular complications of type 2 diabetes.
2. Role of sirtuins in vascular homeostasis
2.1. SIRT1
To date, among all sirtuins, SIRT1 is the most critical modulator of
the vascular function. The prominent role of SIRT1 in the regulation of
vascular homeostasis and diseases is exerted through its action at mul-
tiple cellular levels. Indeed, as described below, this sirtuin is involved in
the promotion of vasodilatory and regenerative functions at EC, EPC,
and SMC levels, as well as in the modulation of monocyte adhesion
and foamcell formation through the regulation of vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1)
expression.
2.1.1. Endothelial cells
SIRT1, highly expressed in EC, maintains normal endothelial func-
tion and controls the angiogenic potential [28,32,33] (Figs. 2, 3).
Under pathological conditions, SIRT1 shuttles between the nucleus
and the cytoplasm to modulate several molecular signaling involved
in the protection of EC against oxidative stress [35]. In particular,
SIRT1 prevents hydrogen peroxide-induced premature senescence of
EC, by deacetylating the tumor suppressor p53, and protects bloodFig. 2. Endothelial targets regulated by sirtuins. Sirtuins, by acting on speciﬁc endothelial targets
cence (p53, eNOs), oxidative stress (MnSOD, FOXOs), cellular energy status (UCP, AMPK), cytos
activated protein kinase; Ang II, angiotensin II; eNOs, endothelial nitric oxide synthase; FOXO,
superoxide dismutase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells;
UCP, uncoupling protein; (+), positively regulated; (−), negatively regulated; (?), unknown.vessels from hyperglycemia-induced endothelial dysfunction through
a mechanism involving the downregulation of p66Shc expression and
transcriptional regulation of eNOS (Fig. 3) [36]. In human EC, the de-
creased expression of SIRT1 during high-glucose treatment also induces
the activation of p53 by increasing its acetylation [37]. This event, in
turn, accelerates EC senescence and induces functional abnormalities.
On the other hand, the activity of SIRT1 has been shown to be rescued
by several compounds, such as resveratrol [6,28], unacylated ghrelin
[38], ginsenoside Rb1 [39], a steroid glycoside found in ginseng, and
paeonol [40]. In particular, unacylated ghrelin, the most abundant
form of circulating ghrelin, protects EC from ROS imbalance in hind
limb ischemia subjected ob/obmice, with a reduction of in vivo EC se-
nescence via SIRT1-mediated p53 and H3K56Ac deacetylation [38].
The molecular basis of the protective effect of paeonol, a phenolic com-
pound isolated from cortex Moutan (tree Peony bark), against the hy-
drogen peroxide-induced premature senescence in human umbilical
EC is attributed to an increase in cell proliferation through the downreg-
ulation of p53 and a decrease of the hydrogen peroxide-induced upreg-
ulation of H3K14Ac and H4K16Ac [40].
Numerous studies describe the protective role of SIRT1 against en-
dothelial senescence [41–45] and SIRT1-mediated regulation of several
senescence-regulating molecules, such as eNOS and FOXOs, in response
to oxidative stress (Fig. 3) [46,47]. SIRT1 mRNA and protein levels pro-
gressively decline during the development of endothelial senescence
which is accelerated by oxidative stress associated with risk factors for
CVD [48]. Overexpression of SIRT1 and the concomitant increased
deacetylation of stress-responsive serine/threonine kinase B1 (LKB1)
prevented the EC senescence in vitro, as well as the stress-induced se-
nescence in mice [36]. Consistent with these ﬁndings, a mouse model
of vascular senescence created by genetically ablating exon 4 of Sirt1
in EC (Sirt1-endo−/−) [49] showed impaired endothelium-dependent
vasorelaxation, angiogenesis, and ﬁbrosis under basal conditions., regulate several processes including inﬂammation (IL-6, TNF-α, NF-Kb, MMP-14), senes-
keletal remodeling (Ang II), and deacetylation of histone H3K14 and H4K16. AMPK, AMP-
Forkhead box O; IL-6, Interleukin 6; MMP-14, metalloproteinase14; MnSOD, manganese
TNF-α, tumor necrosis factor; PAI, plasminogen activator inhibitor, p53, tumor protein;
Fig. 3. Roles of sirtuins in normal and altered endothelial function. SIRT1 is involved in endothelial vascular repair by enhancing FOXO1 levels and counteracting cellular senescence
through the regulation of p53 levels. SIRT1 protects EC against ROS production by decreasing the levels of H3K14Ac and H4K16Ac. Its epigenetic inhibition of PAI-1 expression exerts a
protective effect against vascular endothelial senescence by decreasing the acetylation of H4K16Ac on the PAI-1 promoter region. SIRT2 and SIRT3 regulate ROS production. In addition,
SIRT2 promotes Ang II-induced EC cytoskeletal remodeling. Moreover, SIRT3 acts via FOXO3 activation. The endothelial NO bioavailability via eNOS activation is controlled by both SIRT1
and SIRT6. In human pulmonary microvascular EC, SIRT4 is involved in the inﬂammatory response via a mechanism that probably entails the NF-κB pathway. In EPC, hyperglycemia, ox-
idative stress, and proinﬂammatory cytokines downregulate SIRT1 levels by affecting cell survival through the acetylation/deacetylation status of a wide range of protein targets (SENP1,
p53, NAMPT, and RelA/p65). SIRT1 downregulation is responsible for high p53 acetylation and JNK activation. In EPC, hyperglycemia and oxidative stress also determine an increased bio-
synthesis of PAF and expression of its receptor (PAF-R). SIRT1 expression and upregulation is consistentwith the DDAH2 expression in the course of EPC differentiation. Ang II, angiotensin
II; EC, endothelial cells; EPC, endothelial progenitor cells; eNOs: endothelial nitric oxide synthase; DDAH2, dimethylarginine dimethylaminohydrolase; FOXO1: forkheadbox O transcrip-
tion factor1; NAMPT, nicotinamide phosphoribosyltransferase; NF-κB: nuclear factor-kappaB; PAI-1;plasminogen activator inhibitor-1; PAF platelet-activating factor; PAFR, platelet-acti-
vating factor receptor; PGI2, prostaglandin I2; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPAR-α, peroxisome proliferator-activated receptor alfa;
ROS, reactive oxygen species; SENP1, sentrin/SUMO-speciﬁc protease 1; VEGF: vascular endothelial growth factor; SMC, smoothmuscle cells; JNK, JunNH2-terminal kinase; (?), unknown.
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NO through the deacetylation of lysine 496 and 506 of eNOS [46]. Simi-
larly, in mice subjected to calorie restriction, the beneﬁcial metabolic ef-
fects mediated by SIRT1 activation enhanced the deacetylation of eNOS
(Fig. 3) [46]. A signiﬁcant upregulation of aortic eNOS and SIRT1 expres-
sion induced by physical training has been observed in hypercholester-
olemic mice following oral administration of low doses of red wine, as a
source of resveratrol, a well-known SIRT1 activator [50], suggesting that
modulation of SIRT1mayhave implications for the prevention of athero-
sclerotic lesion progression. Moreover, SIRT1 levels have been found to
be signiﬁcantly higher in EC exposed to physiologically pulsatile ﬂow
than pathophysiologically relevant oscillatory ﬂow [51]. Indeed, the
marked increase in SIRT1 levels caused by laminar ﬂow synergistically
increased the eNOS-derived NO bioavailability in EC via AMP-activated
protein kinase (AMPK) [51]. In response to atheroprotective pulsatile
shear stress, SIRT1 is phosphorylated by Ca2+/calmodulin-dependent
protein kinase kinase β (CaMKKβ) at Ser-27 and Ser-47, whereas abla-
tion of either CaMKKβ or endothelial SIRT1 increases atherosclerosis in
mice [52].
The vasoprotective effect of SIRT1 overexpression has been demon-
strated through an elegant in vitro and in vivo approach by Zhang et al.
[53]. Overexpression of SIRT1 prevented the oxidized low density lipo-
proteins (oxLDL)-induced apoptosis of human umbilical EC via a
marked increase of eNOS expression. Accordingly, endothelial-speciﬁc
overexpression of SIRT1 in ApoE−/−mice induced eNOS and signiﬁcant-
ly blunted the high-fat diet-induced attenuation of endothelium-
dependent relaxation in isolated aortic rings [53]. Most importantly, inApoE−/−mice, endothelial speciﬁc overexpression of SIRT1 also attenu-
ated the aortic plaque development in response to the high-fat diet [53].
A further evidence of the protective role played by SIRT1 against athero-
sclerosis comes from the observation that atherosclerotic plaques from
subjects with impaired glucose metabolism are characterized by in-
creased metalloproteases activity and decreased tissue inhibitor of me-
talloproteinase 3 (TIMP3) expression, which is strictly regulated by
SIRT1 [54]. It has also been proposed that the endothelial protective ef-
fects of SIRT1 include factors other than eNOS-dependent NO produc-
tion [55]. Indeed, no changes in endothelial function or aortic eNOS
activity have been observed between hypercholesterolemic ApoE−/−
SIRT1+/− and ApoE−/− SIRT1+/+ mice [55].
SIRT1-mediated inhibition of plasminogen activator inhibitor-1
(PAI-1) expression exerts a protective effect against vascular endotheli-
al senescence [56]. Indeed, SIRT1 overexpression reverses the increased
PAI-1 expression in senescent EC and aortas of old mice, accompanied
by improved endothelial function and reduced arterial stiffness [56].
In particular, the antisenescence effect of SIRT1-mediated inhibition of
PAI-1 expression occurs through an epigenetic regulatory mechanism
involving the reduction of H4K16Ac level on the PAI-1 promoter [56].
On thewhole, in EC andmacrophages the atheroprotective effects of
SIRT1 are exerted through its anti-thrombotic and anti-inﬂammatory
function by interfering with the NF-κB signaling pathway and by
suppressing the expression of endothelial tissue factor (coagulation fac-
tor III) [57–59]. Post-transcriptional stabilization of SIRT1 by HuR, an
ELAV (embryonic lethal, abnormal vision, Drosophila) family of RNA-
binding proteins, represses inﬂammation- and -hyperglycemia-induced
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represent a strategy to counteract the accelerated vascular disease in
metabolic disorders [60].
The p38-SIRT1 axis has been found markedly relevant in the modu-
lation of the cardiovascular beneﬁts deriving from angiotensin-
converting-enzyme (ACE)-inhibitors [61]. Indeed, the characterization
of the downstream effector of zofenoprilat, an ACE-inhibitor, revealed
that this compound reverts SIRT1 downregulation induced by Ang II
via activation of p38, which directly bounds SIRT1 sequestering it in
the cytoplasm [61]. Under conditions of energy stress, SIRT1 activity
controls the expression of the ACE-2 transcript, whose enhanced
expression is protective in diabetes and CVD, as it counterbalances the
actions of ACE by metabolizing the vasoactive and ﬁbrogenic peptide
Ang II into angiotensin-(1–7) [62]. The epigenetic regulation of ACE-2
by SIRT1 occurs through the binding of SIRT1 to the ACE-2 promoter
which is increased after treatment with the AMP mimic AICAR
(5-amino-4-imidazolecarboxamide riboside) and decreased after
IL-1β treatment [62].
SIRT1 expression levels also inﬂuence cerebral artery relaxation via
endothelial-derived NO andmediate regeneration of blood vessels in is-
chemic neuronal tissue, in part through the deacetylation of hypoxia-
induced factor (HIF) 1α and 2α [63]. However, although endogenous
SIRT1 showed an important function as a stress-induced protector in a
mouse model of oxygen-induced proliferative retinopathy [63], recent
data indicate that overexpression of SIRT1 or treatment with small acti-
vator molecules did not provide additional protection against retinopa-
thy in mice [64].
2.1.2. Endothelial progenitor cells
Maintenance of EC functionality for vascular repair and angiogenesis
is vital to the control of CVD and vascular complications of type 1 or type
2 diabetes. These processes are strictly related to the level and function-
ality of endothelial progenitor cells (EPC), a population of circulating
progenitors displaying the capacity to repair and regenerate vascular
EC [65–70]. SIRT1 deacetylation of FOXO1, a negative regulator of post-
natal angiogenesis, inhibits its antiangiogenic activity in human vascular
EC, as also conﬁrmed in EC-speciﬁc SIRT1-deﬁcient mice model after
acute hind-limb ischemic injury (Fig. 3) [9,33]. EPC exposure to high-
glucose reduces SIRT1 expression levels, blocks deacetylation of
FOXO1 by SIRT1, and reduces eNOS phosphorylation levels (Fig. 3) [71,
72]. Moreover, changes in the acetyl-FOX1 levels are related to treat-
ment of EPC with SIRT1 inhibitor or activator such as nicotinamide and
resveratrol, respectively [71,73]. These data suggest that, in EPC, SIRT1
activity is affected by high-glucose-induced oxidative stress. Consistent
with these ﬁndings, in-vitro and ex-vivo studies demonstrate that the re-
duced EPC functionality in the presence of hyperglycemia or inﬂamma-
tory stimuli relates to lower SIRT1 protein expression levels and
activity [8]. In fact, levels of SIRT1 protein were found to be decreased
in EPC from individualswith type 2 diabetes and, speciﬁcally, to a higher
extent in patients with poor glycemic control than in those with good
glycemic control [8]. Moreover, a randomized, prospective, open label
study on 194 patients with ST-elevation myocardial infarction (STEMI)
undergoing percutaneous coronary intervention (PCI) showed that
the ECP number, differentiation capability, and SIRT1 protein level
are affected by peri-procedural intensive glycemic control [74]. Among
these patients, 88 normoglycemic patients (glucose b 140mg/dl) served
as the control group and the hyperglycemic patients (glucose≥ 140mg/dl)
were randomized to intensive glycemic control (IGC) for almost 24 h
after PCI (n = 54; 80–140 mg/dl) or conventional glycemic control
(CGC, n = 52; 180–200 mg/dl). The EPC from hyperglycemic patients
showed lower number and differentiation and lower SIRT1 levels than
normoglycemic patients. Interestingly, after insulin infusion, the ICG
group, which showed a mean plasma glucose during peri-procedural
period lower than in CGC group, showed higher levels of EPC with
higher capability to differentiate and SIRT1 expression [74]. Tight
glycemic control, for at least 24 h, was associated with a doubledincrease in myocardial salvage of the IGC patients compared to the
CGC group, despite both the intensive and conventionally treated
groups returned to their usual glucose lowering management at the
end of the active phase of the study. This study, which supports the
proposition that stress-hyperglycemia is associated with impaired
myocardial salvage in patients on admission for acute myocardial in-
farction, shows the ﬁrst evidence of the critical role of SIRT1 in the
maintenance of EPC functionality, thus, contributing to an increased
myocardial salvage [74].
The EPC senescence negatively correlates with the expression and
activity of SIRT1 [75,76]. In heterozygousmethylenetetrahydrofolate re-
ductase (Mthfr)-deﬁcient (Mthfr+/−) mice the generation of ROS via
uncoupling of eNOS leads to downregulation of SIRT1 and to increased
EPC senescence [75]. MTHFR counteracts the endothelial dysfunction
linked to hyperhomocysteinemia by converting homocysteine to me-
thionine. In EPC obtained from Mthfr+/−mice, the main source of ROS
was eNOS, as demonstrated by the reduced production of ROS following
treatment with sepiapterin, an analog of BH4.
In patients with chronic obstructive pulmonary disease (COPD), the
epigenetic alterations linked to cigarette smoke-oxidative stress are as-
sociated with a reduced SIRT1 expression in EPC, via the ataxia telangi-
ectasia mutated (ATM) kinase mediated DNA damage response (DDR)
pathway [76]. Inhibition of SIRT1 expression in circulating EPC isolated
form peripheral blood of COPD patients caused an increased senescence
and also an increased acetylation of p53 at Lys-382, suggesting that the
protective effect of SIRT1 against senescence in EPC may be in part me-
diated by deacetylation of p53 (Fig. 3) [76].
SIRT1 expression has been shown to increase with differentiation
of EPC into EC and its interruption inhibits dimethylarginine
dimethylaminohydrolase (DDAH)2, VEGF, and KDR expression, but
shows no effect on ADMA levels [77]. Induction of EPC senescence via
inhibiting SIRT1 is also caused by microRNA-34a (miR-34a) [78].
Overexpression of miR-34a increased the level of acetylated FOXO1,
an effect mimicked in EPC following SIRT1 knockdown [78]. Shear
stress, a mechanical force generated by blood ﬂow, has been recognized
as an important modulator of EPC differentiation. Speciﬁcally, EPC dif-
ferentiation into EC is dependent on shear stress imposed by blood
ﬂow, known to increase SIRT1 level and activity through a PI3k/Akt–
SIRT1–histone H3 acetylation pathway [79]. In particular, the shear
stress signiﬁcantly augmented SIRT1 expression in EPC, whereas SIRT1
siRNA diminished the expression of EC markers and increased the ex-
pression of SMC markers [79].
Post-ischaemic neovascularization has been elegantly demonstrated
to be improved by intracellular NAMPT–NAD(+)–SIRT1 cascade with
Notch signaling involved in the enhanced post-ischaemic neovasculari-
zation (Fig. 3) [80]. Proliferation, migration, and tube formation of cul-
tured BM-derived EPC is suppressed by inhibition of NAMPT whereas
overexpression of NAMPT induced opposite effects through a SIRT1-
dependent enhancement of Notch-1 intracellular domain deacetylation
[80].
2.1.3. Smooth muscle cells
Age-related loss of SIRT1 protein expression in human SMC
correlates with a loss of capacity for vascular repair, diminished stress
response, and increased senescence [81]. In SMC, SIRT1 acts as a modu-
lator of neointima formation and protects against DNA damage, medial
degeneration, atherosclerosis, and hypertension (Fig. 4) [82–84]. As
demonstrated by Li et al. SIRT1 expression decreases in the process of
neointima formation and its overexpression in SMC-speciﬁc human
SIRT1 transgenic mice inhibits neointima formation following vascular
injury [82]. More in details, the reduced neointima formation is linked
to the repression of activator protein-1(AP-1) activity by SIRT1 and
the decreased expression of cyclin D1 and MMP-9 (Fig. 4) [82].
Pro-atherosclerotic effects of SIRT1 in SMC are linked to its reduced
expression due to oxidant stress and LDL [83]. As a consequence, the
inhibition of DNA repair, through the defective deacetylation and
Fig. 4. Role of sirtuins in SMC and immune cells. Section of the blood vessel showing the intima (EC layer, extracellular matrix, and internal elastic lamina) and the SMC layer. SIRT1 takes
part to the mechanisms regulating SMC differentiation, proliferation, and neointima formation though several mechanisms including modulation of stem cell differentiation via enrich-
ment of H3K9-tri-methylation around the SMC gene-promoter regions. SIRT1 overexpression inhibits Ang II-induced vascular remodeling. SIRT1-mediated p53 degradation regulates
SMC lifespan via NAMPT. In addition, SIRT1 inhibits NF-κB/Lox-1 signaling, preventing macrophage foam cell formation. Along with SIRT4 and SIRT6, SIRT1, inhibits monocyte adhesion
and foam cell formation, acting onVCAM-1/ICAM-1 expression. Inmacrophages, SIRT2 acts by increasing iNOS expression. Ang II, angiotensin II; EC, endothelial cells; ICAM-1, intercellular
adhesion molecule 1; iNOS, inducible nitric oxide synthase; Lox-1, lectin-like oxidized low-density lipoprotein (LDL) receptor-1; Mo, monocyte; M , macrophage; NAMPT, nicotinamide
phosphoribosyltransferase; NF- B: nuclear factor-kappaB; p53, tumor protein; SMC, smooth muscle cell; TNF-α, tumor necrosis factor alpha; VCAM-1, vascular cell adhesion protein 1.
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contributes to the persistence of DNA damage and the promotion of
SMC growth arrest, senescence, and apoptosis (Fig. 4) [83]. These pro-
atherosclerotic effects may be augmented by the reduced SIRT1 expres-
sion in EC or macrophages, with increased foam cell formation.
At atherosclerotic plaque level, SIRT1 activation has been proposed
as a possible means of prevention of complications associated with
plaque rupture. Indeed, in SMC, SIRT1 deacetylates the regulatory factor
for X-box (RFX5) and antagonizes RFX5-mediated collagen type I gene
repression by IFN-γ, thus preventingmajor events leading plaque to be-
come unstable and more prone to rupture [85].
In mouse aortas, SIRT1 expression is decreased by Ang II infusion-
induced hypertension (Fig. 4) [84]. SIRT1 overexpression in SMC-
speciﬁc SIRT1 transgenic (SV-Tg) mice prevents the increase in systolic
blood pressure caused by Ang II infusion, alleviates vascular remodeling
in thoracic and renal aortas, reduces the expression of transforming
growth factor-β 1 and signiﬁcantly inhibits ROS generation, vascular in-
ﬂammation, and collagen synthesis in arterial walls [84]. SIRT1 plays
also an essential role in preventing hyperphosphatemia-induced arteri-
al calciﬁcation which can be associated with both premature and repli-
cative senescence (Fig. 4) [86]. SMC replicative senescence is preceded
by a marked decline in the expression and activity of NAMPT [87]. In-
deed, overexpression of NAMPT gene into aging human SMC enhanced
resistance to oxidative stress and reduced fraction of acetylated p53,
along with a lengthened cell life span (Fig. 4) [87]. Importantly, SIRT1
has been identiﬁed as a transcriptional activator in the regulation of
SMC gene program [88]. Speciﬁcally, during SMC differentiation from
murine and human embryonic stem cells, SIRT1 is positively regulatedby miR-34a and modulates the enrichment of H3K9 tri-methylation
around the SMC gene-promoter regions [88].2.1.4. Immune cells in vascular system
In vitro results on human mononuclear U937 cell line indicate that
SIRT1 expression is downregulated during foam cell formation (Fig. 4)
[89]. Activation of SIRT1 by SRT1720 blocks the formation of foam
cells which is paralleled by the increased expression of liver X receptor
(LXR)–ATP-binding cassette (ABC) A1/ABCG1/C-C chemokine receptor
type 7 (CCR7) and a decreased expression of NF-κB and its targets
[89]. Recently, SIRT1 has been shown to take part to the mechanism
regulating monocyte adhesion to EC via miR-34a [90]. Endogenous
miR-34a is critically involved in the ﬂow-dependent regulation of
endothelial inﬂammation, as its expression in EC is downregulated by
atheroprotective physiological high shear stress and upregulated by
atheroprone oscillatory shear stress. Overexpression of miR-34a
increases the protein levels of VCAM-1 and ICAM-1, consequently pro-
moting monocyte adhesion to EC, whereas its blockade decreases
basal VCAM-1 and ICAM-1 protein expression levels. Interestingly,
SIRT1 overexpression has been shown to partially prevent miR-34a-
induced VCAM-1 and ICAM-1 expression on EC (Fig. 4) [90]. In macro-
phages, deacetylation of RelA/p65-NF-κB by SIRT1 suppresses the ex-
pression of Lox-1, a scavenger receptor for oxLDL, thereby, preventing
macrophage foam cell formation (Fig. 4) [57,58]. Moreover, the diabetic
vascular inﬂammation and macrophage inﬁltration in db/db mice has
been shown to be ameliorated by treatment with resveratrol which re-
duces ICAM-1, VCAM-1 and monocyte chemoattractant protein-1
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of SIRT1 [91].
2.2. SIRT2
Genome-wide characterization of the gene expression proﬁle in re-
sponse to SIRT2 knockdown indicates that SIRT2-sensitive genes are in-
volved in multiple cellular functions, such as actin binding ferrous iron
transport, cell aminoacid metabolism, transmembrane receptor protein
serine/threonine kinase signaling, morphogenesis, functions associated
with the trans-Golgi network [92]. In particular, pharmacological inhibi-
tion of SIRT2 attenuated the hydrogen peroxide-induced EC death
(Fig. 3) [92]. However, the speciﬁc gene products involved inmediating
this SIRT2 effect during oxidative stress are still unknown. Moreover,
pretreatment with sirtinol and SIRT2 depletion has been shown to
block the Ang II-induced ECmigration, which also blocked themechan-
ical stretch-induced changes of microtubules, suggesting an emerging
role of SIRT2 in the hypertension-induced vascular remodeling
(Figs. 2, 3) [93]. In macrophages, deﬁciency of SIRT2 ameliorates iNOS,
NO expression, and ROS levels with suppression of LPS-induced activa-
tion of NF-κB, suggesting that this sirtuin can serve as promising candi-
date for treating LPS-induced inﬂammatory diseases (Fig. 4) [94].
2.3. SIRT3
SIRT3 is a key enzyme in the metabolic regulation and ROS homeo-
stasis during vascular disease [95–97] (Fig. 2). SIRT3 increases EC
survival in response to hypoxia [95]. Speciﬁcally, hypoxia elicits an in-
crease of SIRT3 mRNA and protein expression and an increased
deacetylation of FOXO3 [95]. Furthermore, manganese superoxide dis-
mutase (MnSOD), a FOXO3-dependent protein, is upregulated in EC to
facilitate ROS detoxiﬁcation in response to hypoxia [95]. In addition, en-
hancement of SIRT3 activity by resveratrol increases MnSOD/SOD2 en-
zyme activity and expression by upregulation of FOXO3 binding and
transcriptional activity at the MnSOD/SOD2 promoter [96]. Pre-
treatment with resveratrol or SIRT3 overexpression enhanced autopha-
gy and retarded EC apoptosis under long-term oxLDL treatment, where-
as SIRT3 knockdown by siRNAs dramatically increased apoptosis of
oxLDL-treated EC [96]. The control of systemic levels of oxidative stress
exerted by SIRT3 contributes to delaying cardiovascular risk factor
development [98]. Indeed, low-density lipoprotein receptor (LDLR)/
SIRT3 double-knockout (LDLR(−/−)/SIRT3(−/−)) mice fed on high-
cholesterol diet showed no effects on advanced atherosclerotic lesions,
even though levels of systemic oxidative stress were increased [98].
SIRT3 has been proposed to retard cardiovascular risk factor develop-
ment by controlling systemic levels of oxidative stress, limiting expedit-
ed weight gain, and allowing rapid metabolic adaptation [98]. Finally,
SIRT3 is a critical regulator of the mitochondrial function in pulmonary
artery SMC. Mice lacking SIRT3 have increased acetylation and inhibi-
tion ofmitochondrial enzymes and develop spontaneous pulmonary ar-
terial hypertension (Fig. 4) [99].
2.4. SIRT4
SIRT4 has been shown to be involved in endothelial dysfunction as-
sociated with chronic obstructive pulmonary disease (COPD) [100]. In
particular, the SIRT4 expression is downregulated in human pulmonary
microvascular EC treated in vitro with cigarette smoke extract (CSE)
(Figs. 2, 3) [100]. SIRT4 overexpression inhibited CSE-inducedmononu-
clear cell adhesion to pulmonary microvascular EC, mitigating the in-
duction of VCAM-1 and E-selectin (Fig. 4) [100]. Furthermore, SIRT4
overexpression prevented the CSE-induced NF- B activation and its
downstream proinﬂammatory target genes, i.e., interleukin (IL)-1β
(IL-1β), tumor necrosis factor-α (TNF-α), and IL-6 (Fig. 3), suggesting
that SIRT4 protects EC exposed to CSE stress via a mechanism that
may involve the NF-κB pathway [100].2.5. SIRT5
Variants in SIRT5 gene has been found to be associated with the risk
of carotid plaques (Fig. 2) [101]. The associations of 85 single nucleotide
polymorphisms (SNP) in the 11 SIRT and UCP genes with the presence
and number of carotid plaques were investigated in a group of 1018
stroke-free subjects from the Northern Manhattan Study with high-
deﬁnition carotid ultrasonography and genotyping. Interestingly, a
signiﬁcant association between UCP5 variant rs5977238 and the risk
of carotid plaque was observed, as well as an interaction between
smoking, SIRT5, and UCP4 variants for a decreased risk of plaque pres-
ence and plaque number (Fig. 2) [101]. Despite several limitations of
this study, exploring the impact of these genes on vascular aging and
premature atherosclerosis may be helpful for detecting asymptomatic
individuals at increased risk for vascular disease [101].2.6. SIRT6
SIRT6 is a H3K9 and H3K56 deacetylase that speciﬁcally represses
the activities of several transcription factors involved in aging and in-
ﬂammation, including NF-κB, c-JUN, and HIF-1α [102,103]. It prevents
the development of cardiac hypertrophy and heart failure, modulates
glucose metabolism, inhibits EC senescence and inﬂammation, and re-
presses tumor growth. SIRT6 may play a critical role in the regulation
of SMC differentiation in response to the cyclic strain and associations
of SIRT6 and UCP5 genes with carotid plaque may interfere with
NF-κB or HIF-1α and accelerate vascular aging [102,104].
SIRT6 is highly expressed in EC where it possesses a functional role
in protecting from DNA damage and telomere dysfunction [105]. In
fact, SIRT6 protein silencing by siRNA causes the inhibition of EC replica-
tion and increase of EC senescence [105]. An increase of PAI-1 and
ICAM-1 mRNA levels has been observed following SIRT6 depletion
which also causes the lowering of eNOS expression and the EC ability
to form in vitro vessels [105] (Figs. 2, 4). SIRT6 has been shown to be re-
duced in EC following treatment with hydrogen peroxide, while its
overexpression partially reverses the hydrogen peroxide-induced EC
dysfunction and senescence [106] (Fig. 2). To date, themolecular events
through which SIRT6 exerts a protective role at vascular level, regulat-
ing the EC response to stress, ROS production, and hyperglycemia are
still unclear. The involvement of SIRT6 in atherosclerotic progression
of diabetic patients has been recently described [107]. Indeed, evalua-
tion of the effect of incretin-based therapies on the phenotype of athero-
sclerotic carotid plaque from asymptomatic type 2 diabetic patients
(n=52) and non-diabetic patients (n=30) undergoing carotid endar-
terectomy revealed a modulation SIRT6 expression levels [107]. Inter-
estingly, diabetic plaques had more inﬂammation and oxidative stress,
along with a lower SIRT6 expression and collagen content, whereas
plaques fromglucagon-like-peptide-1 (GLP-1)-treated diabetic patients
presented less inﬂammation and oxidative stress along with increased
SIRT6 expression and collagen content, thus indicating a more stable
plaque phenotype [107]. In vitro experiments on EPC and EC showed
that the loss of SIRT6 during short-term exposure to high-glucose is
paralleled by the increased expression of NF- B whereas overexpression
of SIRT6 in the presence of cotreatmentwithGLP-1 receptor agonists re-
lates to a decreased NF- B expression [107].
It has been hypothesized that SIRT6 activity can be regulated
via reactive nitrogen species-mediated posttranslational modiﬁcation
under oxidative and nitrosative stress [108]. Indeed, incubation of
puriﬁed recombinant SIRT6 protein with 3-morpholinosydnonimine
(SIN-1), a peroxynitrite donor that generates NO and superoxide simul-
taneously, increased its tyrosine nitration and decreased its intrinsic
catalytic activity [108]. Interestingly, mass spectrometry analysis
allowed the identiﬁcation of the tyrosine 257 which is nitrated after
SIN-1 treatment and mutated to phenylalanine, causing loss of SIRT6
activity [108].
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This sirtuin has been identiﬁed as a deacetylase of H3K18Ac [109]. As
for SIRT1, SIRT7 can control myocardial development and resist stress-
and aging-associatedmyocardial dysfunction through the deacetylation
of p53 and FOXO1 [110]. SIRT7 regulates HIF-1α and HIF-2α protein
levels via direct physical interactions and its overexpression decreases
HIF-1α and HIF-2α protein levels, HIF transcriptional activity, and tar-
get gene expression [111]. To date, at endothelial level, it has been
only reported a reduced SIRT7 mRNA expression in EC during high-
glucose exposure [112].3. Sirtuin modulators under clinical evaluation for vascular
disease therapy
In the last years, pharmacological modulation of sirtuins has been
widely studied and the observation that SIRT1 activation by resveratrol
shows beneﬁcial effects in CVD increased the interest in developing
more potent SIRT1 activators. In vitro and in vivo experimental models,
along with a consistent number of clinical trials, have focused on the
pharmacokinetics andmetabolismof resveratrol and other sirtuinmod-
ulators, including SRT2183, SRT1460, SRT1720, SRT2379, SRT501,
SRT2104, and SRT3025 [6,28,29,113,114] (Fig. 5). Few patents describ-
ing SIRT inhibitors have been found in 2012–2014 period [115]. Despite
reports on the efﬁcacy of SIRT1 activators/inhibitors are often contradic-
tory, probably due to the limited standardization of the disease models
and limited cross-validation of the ﬁndings, the ability of sirtuin-
activating compounds to treat vascular system injuries, metabolicFig. 5. Sirtuin regulation in vascular homeostasis and diseases. Overview of sirtuin activators/in
eases. AMPK, AMP-activated protein kinase; eNOS, endothelial nitric oxide synthase; FOXO, Fo
peroxide dismutase; NF- B, nuclear factor-kappaB; TNF-α, tumor necrosis factor; p53, tumor pr
unknown.disorders, inﬂammation, wound healing, and endothelial dysfunctions
is under intensive research.
As for the in vitro and in vivo experimental models, activation of
SIRT1 by resveratrol has been shown to be beneﬁcial for the regulation
of oxidative stress, inﬂammation, cellular senescence, and endothelial
dysfunction [73,116]. Resveratrol, by activating SIRT1, impairs synthesis
and increases catabolism of ADMA in young and senescent EC, with a
more accentuated effect in senescent DDAH2 activity [117]. Moreover,
treatmentwith resveratrol inhibits the TNF-α reduced SIRT1 expression
in EC [59] and protects EC from oxLDL-induced oxidative damage [118].
Activation of SIRT1 by the compound BTM-0512, a resveratrol deriva-
tive, showed a beneﬁcial role on high glucose-induced EC dysfunction
[119]. In mice model, the compound SRT1720, a potent SIRT1 activator
[6], reduces glucose levels and liver triglyceride content and recover
mitochondrial functions after acute oxidant injury [120–122]. Further-
more, an extension in lifespan and an improved general health
has been observed in mice fed on standard diet with SRT1720 supple-
mentation [123]. Among the sirtuin inhibitors, the sirtinol and its analog
m- and p-sirtinol, which act on SIRT1 and SIRT2, show a protective role
against inﬂammation in microvascular EC [124–126]. Activation of
SIRT1 by SRT3025, a novel SIRT1 activator, has beendemonstrated to re-
duce hepatic proprotein convertase subtilisin/kexin type 9 (Pcsk9) se-
cretion and to enhance LDL receptor expression in atherosclerosis-
prone ApoE−/− mice, leading to a decreased plaque formation [127].
These data suggest a novel mechanism that links SIRT1 to the metabo-
lism of LDL-cholesterol in vitro and in vivo.
Among natural compounds able to modulate SIRT1, stachydrine, a
proline betaine present in considerable quantities in juices from fruits
of the Citrus genus, inhibits the deleterious effect of high‐glucosehibitors that modulate different cellular targets involved in vascular homeostasis and dis-
rkhead box O; IL-6, Interleukin 6; MMP-14, metalloproteinase14; MnSOD, manganese su-
otein; UCP, uncoupling proteins; (+), positively regulated; (−), negatively regulated; (?),
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particular, stachydrine counteracts the detrimental effects of high‐
glucose by downregulating p16INK4A protein levels and by preventing
the inhibition of SIRT1 activity and expression [128]. However, to date,
the mechanism by which stachydrine acts on p16INK4A and SIRT1 ex-
pression is not fully elucidated. Multiple regulatory mechanisms are
known to take part to the signal transduction pathway responsible for
SIRT1 regulation in the endothelial dysfunction during altered glucose
homeostasis [129]. Indeed,modulation of SIRT1 can be achieved by reg-
ulating the enzymatic activity through substrate availability or post-
translational modiﬁcations and by acting at expression levels through
transcription factors, RNA binding proteins, miRNAs, or ubiquitin–pro-
teasome system [129].
As for the ongoing clinical trials aimed at evaluating the role of
sirtuin modulators in the prevention or treatment of endothelial dys-
function and reduced new blood vessel growth, the current trials
(http://clinicaltrials.gov/) are reported in Table 1. A randomized,
completed placebo-controlled study investigates different doses of
SRT3025, a novel SIRT1 activator, in normal healthy volunteers
(NCT01340911). A phase I trial is evaluating the effect of oral trans-
resveratrol extract from Polygonum cuspidatum on the SIRT1 expression
in skeletal muscle of 10 patients with type 2 diabetes (NCT01677611).
Another study, aimed at examining the effect of chronic administration
of polyphenols contained in RedGrape Cells powder on SIRT1mRNAex-
pression in patients with type 2 diabetes, is currently recruiting partic-
ipants (NCT01938521). Moreover, another study, still recruiting
participants (NCT01668836), will evaluate SIRT1 inﬂuence in vascular
reactivity, antioxidant capacity, and markers of inﬂammation before
and after the interventions with caloric restriction or resveratrol
administration.
An advanced clinical trial (Phase 4) is actually investigating the ef-
fects of omega 3 supplementation and its concurrent supplementation
with vitamin E on the serum levels of antioxidant enzymes and the ex-
pressions of the PGC-1a, hTERT, FOXO1, FOXO3a, SIRT1, SIRT3, SIRT6
genes in peripheral blood mononuclear cells from patients with coro-
nary artery disease (NCT02011906).
A clinical trial that evaluated the safety of oral SRT2104, an SIRT1 ac-
tivator, and its effects on vascular dysfunction in otherwise healthy cig-
arette smokers and subjects with type 2 diabetes mellitus has been
recently completed and results are expected (NCT01031108). This
study was set up to explore the effects of SRT2104 on potential bio-
markers of activity for glucose control (HbA1c, glycated albumin and
fructosamine) and/or SIRT1 activation. Venkatasubramanian et al.
[130] reported that in a randomized double-blind, placebo-controlled
crossover trial, the treatment of twenty-four healthy cigarette smokers
with SRT2104 was associated with an 11% mean reduction in serumTable 1
SIRT1modulators under clinical evaluation.NIHongoing clinical trials evaluating the safety of SIR
of type 2 diabetes (http://clinicaltrials.gov/).
Compound Sponsor
Trans-resveratrol from Polygonum cuspidatum Khoo Teck Puat Hospital
Resveratrol InCor Heart Institute
Resveratrol University of Aarhus
Omega 3 and vitamin E supplementation Tehran University of Medical Sciences
Polyphenols contained in red grape cells Tel Aviv University
SRT2104 Sirtris, GSK Company
SRT2104 GlaxoSmithKline
SRT2104 Sirtris, GSK Company
SRT2104 Sirtris, GSK Company
SRT2104 Sirtris, GSK Company
SRT2104 GlaxoSmithKline
SRT2104 Sirtris, GSK Company
SRT2379 GlaxoSmithKline
SRT3025 Sirtris, GSK CompanyLDL cholesterol concentrations, but without demonstrable differences
in vasomotor function, endothelial function, or platelet activation as-
sessments compared with placebo. The favorable effects on lipid proﬁle
suggested that SIRT1 activation may have a beneﬁcial role in patients at
risk of developing or with established CVD.
The safety and tolerability of SRT2104 (0.25, 0.5, 1.0, and 2.0 g/day)
when administered once daily for 28 consecutive days in type 2 diabetic
subjects is under Phase 2 trial evaluation (NCT00937326). Another clin-
ical study on the pharmacokinetic proﬁle of SRT2104 (0.03, 0.1, 0.25, 0.5,
1.0, 2.0, and 3.0 g/day) after a single dose andmultiple administrations in
healthy male volunteers has been completed and results are expected
(NCT00933530). Moreover, three completed Phase 1 clinical studies,
with results not yet posted, evaluated the bioavailability of and the phar-
macokinetics of SRT2104 as a 250 mg suspension (NCT00937872), as a
single 500 mg dose oral suspension (NCT00938275), or 2.0 g/day
(NCT01018017) in type 2 diabetic patients and deﬁned the intravenous
pharmacokinetics of this compound. Likewise, SRT2379, another selec-
tive small-molecule activator of SIRT1, has been investigated in a Phase
1 clinical trial (NCT01018628) aimed at evaluating its effect on plasma
concentrations of ﬁbroblast growth factor 21 (FGF21) and at identifying
other possible biomarkers suitable for future clinical assessment of oral
SIRT1 activators for the treatment of type 2 diabetes.
4. Conclusions and perspectives
Mammalian sirtuins, critical modulators of the signaling pathways
controlling age-related diseases, have emerged as promising therapeu-
tic targets for CVDmanagement. Sirtuins enhance stress resistance, im-
prove the ability to counteract oxidative stress, and modulate cell
metabolism and inﬂammatory responses, thus, offering the possibility
to attenuate or prevent CVD through appropriate modulation with spe-
ciﬁc activators/inhibitors. To date, the most effective class of sirtuin ac-
tivators has been reported for SIRT1, whose activation has emerged as a
promising therapeutic approach to treat vascular disorders and to re-
tard aging related CVD. However, future investigations are needed to
clarify the complete mechanism of action of SIRT1 and other sirtuins
at endothelial level. Indeed, many questions remain to be addressed,
with particular regard to those concerning the potential role of the
other sirtuins, such as SIRT6, in vascular diseases. In the light of the con-
sistent number of the ongoing clinical trials with either SIRT1 inhibitors
or activators, it is conceivable that in the next future one or more of
them will enter in the clinical practice. However, the development of
novel compounds, as well asmore isoform-speciﬁc activators and/or in-
hibitors for SIRT1 should be pursued without neglecting further re-
search to evaluate possible negative effects associated with chronic
sirtuin activation.T1modulators in subjectswith endothelial dysfunction inCVD andvascular complications
Status Phase Condition NIH code
Completed 1 Type 2 diabetes NCT01677611
Recruiting – Vascular system injuries,
endothelial dysfunction
NCT01668836
Completed – Metabolic syndrome, obesity NCT01150955
Enrolling by invitation 4 Coronary artery disease NCT02011906
Recruiting 0 Type 2 diabetes NCT01938521
Completed 1 Type 2 diabetes NCT01031108
Completed 2 Type 2 diabetes NCT01018017
Completed 1 Type 2 diabetes NCT00937872
Completed 2 Type 2 diabetes NCT00937326
Completed 1 Type 2 diabetes NCT00938275
Completed 1 Type 2 diabetes NCT00933062
Completed 1 Type 2 diabetes NCT00933530
Completed 1 Type 2 diabetes NCT01018628
Completed 1 Type 2 diabetes NCT01340911
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